Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

18.27 0.38

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

18.2

Massimo

18.33

Metriche Chiave

By Trading Economics

Entrata

-607K

-51M

Vendite

-28M

100M

EPS

-0.46

Margine di Profitto

-51.215

Dipendenti

1,784

EBITDA

4.1M

-44M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+68.97% upside

Dividendi

By Acuity

Utili prossimi

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-279M

2.1B

Apertura precedente

17.89

Chiusura precedente

18.27

Notizie sul Sentiment di mercato

By Acuity

100%

0%

319 / 340 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

1 ago 2026, 19:01 UTC

News
Correlated Moves

Ethereum is trading lower, reflecting a broader decline in correlated assets. It remains below its 20-day moving average amid routine market fluctuations.

1 ago 2026, 00:06 UTC

Social Media
News

TLT trades lower in after-market hours, reflecting a historically bearish period for bonds and targeting the $80 level amid rising interest rate expectations.

1 ago 2026, 00:06 UTC

News

Geopolitical tensions with Iran have boosted the United States Oil Fund LP, following President Trump's ordered military offensive in response to attacks on U.S. troops.

1 ago 2026, 00:06 UTC

News

Ameriprise Financial Inc shares are lower in after-market trading, despite strong second-quarter revenue of $4.90 billion and adjusted EPS of $11.07.

1 ago 2026, 00:02 UTC

News

UBS raised its price target on Hershey Co to $198, maintaining a Neutral rating. Shares are trading higher during after-market hours.

1 ago 2026, 00:02 UTC

News

Lattice Semiconductor shares are lower in after-market trading following a cautionary report citing declining sales and rising costs, with shares priced at $124.53.

1 ago 2026, 00:02 UTC

News

Snap Inc. shares rose to about $4.70 in after-market hours, supported by bullish options activity ahead of its August 3 earnings report.

1 ago 2026, 00:02 UTC

News
Social Media

NVIDIA Corp shares are lower in after-market hours amid broader market declines, despite recent strong performance relative to peers and a weekly gain.

1 ago 2026, 00:02 UTC

News

Lockheed Martin secured a $107.29 million Navy contract for VH-92A rotor blade design, boosting shares in after-market hours.

1 ago 2026, 00:02 UTC

News
Correlated Moves

JPMorgan Chase & Co shares are lower in after-market trading amid ongoing market rotation and rising bond yields affecting investor sentiment.

1 ago 2026, 00:02 UTC

News

KKR & Co Inc reported record Q2 revenue of $6.31 billion. Shares declined in after-market trading despite strong earnings and net income growth.

1 ago 2026, 00:02 UTC

News

Exponent Inc shares are trading lower in after-market hours after UBS lowered its price target to $72 while maintaining a Neutral rating.

1 ago 2026, 00:02 UTC

News

Bloom Energy Corp is declining in after-market hours amid a class action lawsuit alleging securities fraud and broader market pressures.

1 ago 2026, 00:01 UTC

News

Quantum Corp shares are higher in after-market trading, supported by positive developments in the quantum computing industry and strong investor interest in the sector.

1 ago 2026, 00:01 UTC

News

UBS raised its price target on Bright Horizons to $88, as shares gain in after-market trading following three sessions of declines.

1 ago 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

1 ago 2026, 00:01 UTC

News

Newell Brands Inc shares are lower in after-market hours amid overall market declines. The company entered a five-year credit facility of up to $800 million.

1 ago 2026, 00:01 UTC

News

UBS raised its price target on Valero Energy Corp to $355, contributing to shares' gain during after-market hours on Friday.

1 ago 2026, 00:01 UTC

News

UBS maintains Buy rating on Saia Inc, lowering price target to $504. Shares are higher in after-market trading following the adjustment.

1 ago 2026, 00:01 UTC

News

Alnylam Pharmaceuticals shares are lower in after-market hours, reflecting broader market declines despite a strong second-quarter revenue of $1.2 billion.

1 ago 2026, 00:01 UTC

News

American Electric Power reported Q2 earnings of $1.36 per share and raised its 2026 guidance to $6.25 to $6.55, driving shares higher in after-market hours.

1 ago 2026, 00:01 UTC

News

Clean Energy Fuels Corp is trading lower in after-market hours following a cautionary analysis highlighting its subpar revenue growth and high production costs.

1 ago 2026, 00:01 UTC

News

Chevron Corp has reached an accord with Iraq to invest in two oil fields, enhancing production capabilities. Shares are trading higher in after-market hours.

31 lug 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Welltower and raised its price target to $275. Shares are modestly higher in after-market trading.

31 lug 2026, 23:56 UTC

News

Citigroup maintained its Buy rating on Neurocrine Biosciences and raised its price target to $249. Shares are higher in after-market trading.

31 lug 2026, 23:51 UTC

Social Media
Correlated Moves
News

Meta Platforms Inc shares are lower in after-market hours, pressured by broader market weakness and concerns over rising AI spending following a disappointing earnings report.

31 lug 2026, 23:46 UTC

News

3M shares declined in after-market trading amid concerns over insider selling by EVP Kevin H. Rhodes, who sold $1.3 million worth of stock.

31 lug 2026, 23:41 UTC

Social Media
News
Correlated Moves

Goldman Sachs shares declined in after-market trading amid broader market turmoil and hedge fund degrossing linked to losses on leveraged AI investments.

31 lug 2026, 23:41 UTC

News

JPMorgan Chase & Co. shares are lower in after-market trading following a note highlighting ongoing market rotation and challenges from rising long-term Treasury yields.

31 lug 2026, 23:36 UTC

News

Carvana shares declined in after-market trading following Citigroup's price target cut to $90, amid broader market weakness from Apple's disappointing guidance.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

68.97% in crescita

Previsioni per 12 mesi

Media 30.87 USD  68.97%

Alto 44 USD

Basso 21.6 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

319 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat